LLY

981.86

-0.29%↓

JNJ

243.2

+0.67%↑

ABBV

221.94

+1.03%↑

NVS

154.64

+1.01%↑

AZN

192.02

+1%↑

LLY

981.86

-0.29%↓

JNJ

243.2

+0.67%↑

ABBV

221.94

+1.03%↑

NVS

154.64

+1.01%↑

AZN

192.02

+1%↑

LLY

981.86

-0.29%↓

JNJ

243.2

+0.67%↑

ABBV

221.94

+1.03%↑

NVS

154.64

+1.01%↑

AZN

192.02

+1%↑

LLY

981.86

-0.29%↓

JNJ

243.2

+0.67%↑

ABBV

221.94

+1.03%↑

NVS

154.64

+1.01%↑

AZN

192.02

+1%↑

LLY

981.86

-0.29%↓

JNJ

243.2

+0.67%↑

ABBV

221.94

+1.03%↑

NVS

154.64

+1.01%↑

AZN

192.02

+1%↑

Strona główna・Stock List・Zai Lab Ltd ADR

Zai Lab Ltd ADR

Open

SectorHealthcare

19.02 4.11

Buy Sell

Overview

Share price change

24h

Current

Min

18.27

Max

18.93

Key metrics
By Trading Economics
Income	-14M -50M
Sales	12M 128M
Profit margin	-39.506
Employees	1,784
EBITDA	-17M -48M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+96.68% upside

Dividends
By Dow Jones
Next Earnings	7 maj 2026

Market Stats
By TradingEconomics
Market Cap	-95M 2.1B
Previous open	14.91
Previous close	19.02

News Sentiment

By Acuity

50%

133 / 351 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

28.13 / 31.12 Support & Resistance

Zai Lab Ltd ADR Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

15 mar 2026, 21:14 UTC

Major News Events

Week Ahead for FX, Bonds: Central Bank Decisions -2-

15 mar 2026, 21:14 UTC

Major News Events

Week Ahead for FX, Bonds: Central Bank Decisions in Focus After Jump in Energy Prices

16 mar 2026, 00:00 UTC

Major News Events

Hack on U.S. Medical Company Shows Reach of Iran's Cyber Capabilities -- WSJ

15 mar 2026, 23:45 UTC

Market Talk

Nikkei May Decline on Concerns About Prolonged Middle East Conflict -- Market Talk

15 mar 2026, 23:44 UTC

Market Talk

Major News Events

Gold Falls as Rising Energy Prices Exacerbate Inflation Worries -- Market Talk

15 mar 2026, 23:35 UTC

Market Talk

Major News Events

Oil Futures Rise on Supply Disruption Concerns -- Market Talk

15 mar 2026, 23:00 UTC

Acquisitions, Mergers, Takeovers

Micron Completes Acquisition Of PSMC's Tongluo P5 Site In Taiwan >MU

15 mar 2026, 22:37 UTC

Market Talk

March Rate Hike Would Distance RBA From Government's May Budget -- Market Talk

15 mar 2026, 22:18 UTC

Market Talk

RBA's Likely Hike Motivated By Inflation, Not Middle East -- Market Talk

15 mar 2026, 22:14 UTC

Earnings

Genscript Biotech 2025 Adj Net $230.35M Vs. Adj Net $59.83M>1548.HK

15 mar 2026, 22:14 UTC

Earnings

Genscript Biotech: 2025 Loss Due to High Base Effect, One-off Unrealized Gains Seen Last Year >1548.HK

15 mar 2026, 22:14 UTC

Earnings

Genscript Biotech 2025 Rev $959.53M Vs. $594.49M >1548.HK

15 mar 2026, 22:14 UTC

Earnings

Genscript Biotech 2025 Loss $532.83M Vs. Net $2.96B >1548.HK

15 mar 2026, 22:14 UTC

Earnings

Genscript Biotech: 2025 Rev Supported by Substantial Increase in License Revenue>1548.HK

15 mar 2026, 22:00 UTC

Major News Events

Oil Industry Warns Trump Administration Energy Crisis Will Likely Worsen -- WSJ

15 mar 2026, 22:00 UTC

Major News Events

Oil Industry Warns Trump Administration Energy Crisis Will Likely Worsen -- WSJ

15 mar 2026, 03:00 UTC

Major News Events

For Xi, Iran War Reinforces View of U.S. as Dangerous Superpower -- WSJ

14 mar 2026, 15:00 UTC

Major News Events

Iran War Delivers Windfall to America's Oil Country -- WSJ

14 mar 2026, 02:03 UTC

Earnings

This Copper Stock Is Worth Mining for Profits -- Barrons.com

14 mar 2026, 01:32 UTC

Acquisitions, Mergers, Takeovers

Bill Ackman's Pershing Square IPO Is Back On -- Barrons.com

14 mar 2026, 00:29 UTC

Acquisitions, Mergers, Takeovers

13D Filings -- Barrons.com

13 mar 2026, 22:27 UTC

Market Talk

Major News Events

Bahrain Faces Uncertainty But Has Support Amid War, S&P Says -- Market Talk

13 mar 2026, 22:13 UTC

Market Talk

Major News Events

Saudi Arabia Seen as Able to Weather Iran Conflict, S&P Says -- Market Talk

13 mar 2026, 22:04 UTC

Market Talk

Major News Events

Emirate of RAK Outlook Stable Despite Iran War, S&P Says -- Market Talk

13 mar 2026, 22:00 UTC

Acquisitions, Mergers, Takeovers

Trump Administration Set to Receive $10 Billion Fee for Brokering TikTok Deal -- WSJ

13 mar 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

13 mar 2026, 20:50 UTC

Market Talk

Major News Events

Financial Services Roundup: Market Talk

13 mar 2026, 20:02 UTC

Market Talk

Canada Rate Hike in 2026 Would Mark 'Extraordinarily Bad' Policy -- Market Talk

13 mar 2026, 19:50 UTC

Market Talk

Major News Events

Oil Posts Weekly Gains As Middle East Conflict Drags On -- Market Talk

13 mar 2026, 19:35 UTC

Major News Events

Oil Prices Hover Near $100. India Asks Iran to Allow 23 Tankers Through Strait of Hormuz. -- Barrons.com

Peer Comparison

Price change

Zai Lab Ltd ADR Forecast

Price Target

By TipRanks

96.68% upside

12 Months Forecast

Average 36.13 USD 96.68%

High 47 USD

Low 21.8 USD

Based on 6 Wall Street analysts offering 12 month price targets forZai Lab Ltd ADR - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

6 ratings

Buy

Hold

Sell

Based on 6 analysts giving stock ratings to Zai Lab Ltd ADR - Dist in the past 3 months.

Technical Score

By Trading Central

28.13 / 31.12Support & Resistance

Recent bearish events outweigh bullish events.

All events are bullish.

Sentiment

By Acuity

133 / 351 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.